Zymeworks Inc. (NYSE: ZYME) started the day on November 23, 2022, with a price increase of 3.61% at $8.04. During the day, the stock rose to $8.15 and sunk to $7.6894 before settling in for the price of $7.76 at the close. Taking a more long-term approach, ZYME posted a 52-week range of $4.11-$21.44.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 19.40%. Meanwhile, its Annual Earning per share during the time was -24.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -14.70%. This publicly-traded company’s shares outstanding now amounts to $66.48 million, simultaneously with a float of $54.47 million. The organization now has a market capitalization sitting at $522.84 million. At the time of writing, stock’s 50-day Moving Average stood at $6.52, while the 200-day Moving Average is $6.36.
Zymeworks Inc. (ZYME) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Zymeworks Inc.’s current insider ownership accounts for 0.10%, in contrast to 78.50% institutional ownership. According to the most recent insider trade that took place on Nov 10, this organization’s Chief Medical Officer sold 2,475 shares at the rate of 8.10, making the entire transaction reach 20,045 in total value, affecting insider ownership by 14,449. Preceding that transaction, on Mar 10, Company’s Chief Operating Officer sold 2,979 for 6.88, making the whole transaction’s value amount to 20,496. This particular insider is now the holder of 13,276 in total.
Zymeworks Inc. (ZYME) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 6/29/2022, the organization reported -$0.97 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.96) by -$0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
Zymeworks Inc.’s EPS decrease for this current 12-month fiscal period is -14.70% and is forecasted to reach -1.21 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.00% through the next 5 years, which can be compared against the -24.10% growth it accomplished over the previous five years trading on the market.
Zymeworks Inc. (NYSE: ZYME) Trading Performance Indicators
Let’s observe the current performance indicators for Zymeworks Inc. (ZYME). It’s Quick Ratio in the last reported quarter now stands at 3.30. The Stock has managed to achieve an average true range (ATR) of 0.64. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 17.49.
In the same vein, ZYME’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.63, a figure that is expected to reach 1.43 in the next quarter, and analysts are predicting that it will be -1.21 at the market close of one year from today.
Technical Analysis of Zymeworks Inc. (ZYME)
If we take a close look at the recent performances of Zymeworks Inc. (NYSE: ZYME), its last 5-days Average volume was 0.53 million that shows plunge from its year to date volume of 1.25 million. During the previous 9 days, stock’s Stochastic %D was recorded 47.04% While, its Average True Range was 0.62.